Becton, Dickinson and Company (BDX) has seen a significant surge in share acquisition by Victory Capital Management Inc. and Machina Capital S.A.S., reinforcing its position in their portfolios. There has been consistent surpassing of Q4 and Q2 earnings and revenue estimates, attracting praise from Barclays and boosting their price target to $312.00. BDX's fiscal Q2 earnings snapshot and Q2 Outlook show strong key metrics, leading them to be labeled a value stock. Despite facing macroeconomic headwinds in Q4, BDX's earnings have managed to exceed expectations, backed by outstanding earnings per share (EPS). BDX investors have seen a promising return of 26% over the past five years. In response to strong Q2 earnings, BDX has revised its FY24 view and raised its fiscal 2024 guidance. However, the stock fell after the announcement of lower-than-expected 2024 guidance. Yet, BDX has been named among Fortune's most innovative companies, showing their dedication towards innovation in the biotech market. Becton Dickinson's dividend analysis indicates a reliable revenue source, thus making it a safe investment for income investors. Despite a decline in the stock, BDX's solid financials can't be overlooked. Ultimately, BDX's fundamentals appear strong enough to warrant buying, despite the stock's recent weakness.
Becton Dickinson and BDX News Analytics from Wed, 04 Oct 2023 07:00:00 GMT to Wed, 08 May 2024 11:07:49 GMT -
Rating 6
- Innovation 8
- Information 8
- Rumor 6
